Related Experiment Video
Updated: Mar 17, 2026
07:33
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
24.1K
Approach to lymphogranuloma venereum
Patrick O'Byrne1, Paul MacPherson2, Stephane DeLaplante3
1Associate Professor of Nursing at the University of Ottawa in Ontario. pjobyrne@uottawa.ca.
Canadian Family Physician Medecin De Famille Canadien
|July 15, 2016
Summary
Lymphogranuloma venereum (LGV), a Chlamydia trachomatis serovar L, is resurging and presents differently than other chlamydia strains. Primary care providers must recognize LGV for appropriate diagnosis and treatment.
Area of Science:
- Infectious Diseases
- Microbiology
- Public Health
Background:
- Lymphogranuloma venereum (LGV) is caused by specific serovars (L1-L3) of Chlamydia trachomatis.
- Unlike other Chlamydia trachomatis serovars (A-K) causing superficial mucosal infections, LGV serovars can invade lymphatic tissue.
Observation:
- A resurgence of LGV has been observed since 2003, particularly among men who have sex with men in Western countries.
- LGV infection progresses through three distinct clinical stages: inoculation lesion, lymphatic invasion (inguinal or rectal syndrome), and tissue destruction.
Findings:
- LGV presents with unique symptoms and a distinct clinical course compared to other chlamydial infections.
- LGV requires a different treatment regimen than non-LGV serovars of Chlamydia trachomatis.
Implications:
- Primary care providers should consider LGV in their differential diagnosis due to its increasing prevalence.
- Timely recognition and appropriate treatment are crucial for managing LGV and preventing long-term complications.
